Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis
JAMA Dermatologyn=259
💡
Zasocitinib ≥5 mg daily improved skin clearance vs placebo over 12 weeks in moderate to severe plaque psoriasis, with similar short-term safety and...
Clinical insight